✦ LIBER ✦

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer

✍ Scribed by Peter E Clark; David M Peereboom; Robert Dreicer; Howard S Levin; Sarah B Clark; Eric A Klein

Book ID: 117263330
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 123 KB
Volume: 57
Category: Article
ISSN: 0090-4295
DOI: 10.1016/s0090-4295(00)00914-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of neoadjuvant docetaxel

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer

✍ Robert Dreicer; Cristina Magi-Galluzzi; Ming Zhou; Jason Rothaermel; Alwyn Reuth 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 109 KB

Neoadjuvant docetaxel/estramustine prior

Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial

✍ William Y. Kim; Young E. Whang; Raj S. Pruthi; Maria Q. Baggstrom; W. Kimryn Rat 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 155 KB

Phase II trial of neoadjuvant docetaxel

Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer

✍ Jacqueline Vuky; Christopher Porter; Christina Isacson; Matthew Vaughan; Paul Ko 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 1 views

## Abstract ## BACKGROUND: Prostate cancer trials investigating neoadjuvant hormonal therapy, followed by surgery, have demonstrated that elimination of all tumor cells from the primary site is rare. The authors report a phase 2 trial assessing the efficacy and toxicity of docetaxel and gefitinib

Phase II Trial of Neoadjuvant Bevacizuma

Phase II Trial of Neoadjuvant Bevacizumab, Capecitabine, and Radiotherapy for Locally Advanced Rectal Cancer

✍ Christopher H. Crane; Cathy Eng; Barry W. Feig; Prajnan Das; John M. Skibber; Ge 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 116 KB

Prognostic factors for and outcome of lo

Prognostic factors for and outcome of locally advanced prostate cancer after radical prostatectomy

✍ Chao-Yu Hsu; Mark F. Wildhagen; Hein Van Poppel; Chris H. Bangma 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB

A phase II trial of estramustine and eto

A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407)

✍ Kenneth J. Pienta; Emily I. Fisher; Mario A. Eisenberger; Glenn M. Mills; J. Wen 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

BACKGROUND. The combination of oral estramustine and oral etoposide has generated response rates of 40±50% in patients with hormone refractory prostate cancer in single institution trials. This study tested this regimen in a multi-institutional setting. METHODS. Fifty-®ve patients were accrued over